The Biotech Dance: Novartis Eyes Avidity in a Blockbuster Bid

Novartis' Cosentyx Shines in Long-Term Trial, Offering Hope for Chronic Joint Pain Sufferers

A New Dawn for ITP Patients: Telitacicept Shows Remarkable Promise in Autoimmune Disorder

Tariff Relief: US Postpones Duties on Singaporean Pharma Amidst Supply Chain Concerns

The Biotech Bonanza: Unearthing Tomorrow's Investment Gems in a Volatile Market

A Pivotal Moment: HHS Advances Major Drug Pricing Rule for Review

Pharma's Big Win: How a Judge's Ruling Ignited Big Pharma Stocks

Transatlantic Tremors: How US Drug Pricing Reforms Are Reshaping the Global Pharmaceutical Landscape

Trump's Bold Vision: Pushing for Direct Drug Deals to Slash Costs

Apellis Pharmaceuticals Faces Investor Jitters as Goldman Sachs Issues "Sell" Rating on Escalating Competitive Threats

Amneal Pharmaceuticals Eyes Major Market Entry with Xolair Biosimilar, Pledging Affordable Relief

Novartis Plots Strategic Price Adjustments in US as Trump's MFN Deadline Looms

Roche's Strategic Investment Ignites Excitement in the MASH Drug Development Landscape

Trump's Biotech Revolution: Unleashing a Staggering $350 Billion Investment Wave

Unlocking Monopar's Potential: A Speculative Bet on Imminent Cancer Breakthroughs

Amgen may be evaluating Cytokinetics bid; CYTK wants $130 $145 a share report

Novartis said to have backed away from a deal for Cytokinetics

Cytokinetics plunges amid no deal announcement as JPMorgan conf set to end